Methods	Six-week randomised, double-blind study.
Participants	Outpatients fulfilling DSM-III criteria for major depression (lasting more than 1 month), with a score of at least 20 on the HDRS. Age range: over 18 years old. Exclusion criteria: pregnancy, lactation, absence of contraception, serious suicide risk, glaucoma, presence of cardiovascular arrythmias, hypertension, serious medical illness, including hepatic, renal, respiratory, hematologic disease, histiory of seizure, severe allergies or multiple drug reaction, psychotic patients and patients with DSM-III diagnosis of organic mental disorder, substance abuse disorder within the past year, schizophrenia, paraniod disorder, bipolar disorder, use of MAOI in the past 14 days, lithium or any other psychotropic drug, use of trazodone or fluoxetine within 4 weeks of study entry
Interventions	Fluoxetine: 21 participants. Trazodone : 19 participants. Fluoxetine dose range: 20-60 mg/day. Trazodone dose range: 50-400 mg/day.
Outcomes	Hamilton Rating Scale for Depression (HDRS-17), CGI.
Notes	Funding: unclear
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear